Keywords: Genzyme, Sanofi-Aventis, M&A, Teriflunomide, Multiple sclerosis

Genzyme snubs Sanofi-Aventis’ $18.5 billion offer; French drugmaker reports good data for MS drug teriflunomide

Article | 31 August 2010

Print This

It was a bad and a good news day yesterday for French drug major Sanofi-Aventis (Euronext; SAN), when its $18.5 billion ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in